AbCellera Biologics (ABCL) Debt to Equity (2020 - 2025)
AbCellera Biologics' Debt to Equity history spans 6 years, with the latest figure at $0.01 for Q1 2025.
- For the quarter ending Q1 2025, Debt to Equity fell 81.16% year-over-year to $0.01, compared with a TTM value of $0.01 through Mar 2025, down 81.16%, and an annual FY2024 reading of $0.01, down 82.52% over the prior year.
- Debt to Equity for Q1 2025 was $0.01 at AbCellera Biologics, up from $0.01 in the prior quarter.
- The five-year high for Debt to Equity was $0.05 in Q2 2023, with the low at $0.01 in Q4 2024.
- Average Debt to Equity over 5 years is $0.03, with a median of $0.02 recorded in 2022.
- Year-over-year, Debt to Equity skyrocketed 136.16% in 2022 and then tumbled 82.52% in 2024.
- Tracing ABCL's Debt to Equity over 5 years: stood at $0.02 in 2021, then skyrocketed by 60.33% to $0.04 in 2022, then increased by 22.19% to $0.04 in 2023, then tumbled by 82.52% to $0.01 in 2024, then increased by 11.97% to $0.01 in 2025.
- Per Business Quant, the three most recent readings for ABCL's Debt to Equity are $0.01 (Q1 2025), $0.01 (Q4 2024), and $0.02 (Q3 2024).